{"id":7008,"date":"2023-05-08T14:24:30","date_gmt":"2023-05-08T12:24:30","guid":{"rendered":"https:\/\/www.izkf.med.fau.de\/?page_id=7008"},"modified":"2025-09-04T13:55:01","modified_gmt":"2025-09-04T11:55:01","slug":"gefoerderte-projekte","status":"publish","type":"page","link":"https:\/\/www.izkf.med.fau.de\/en\/elan\/anschubfinanzierung\/gefoerderte-projekte\/","title":{"rendered":"Current Pilot Projects"},"content":{"rendered":"<div class=\"cris\"><div class=\"cris-fields\"><h2>ELAN-Pilot Projects<\/h2><p>ELAN pilot projects provide funds for junior researchers (postdocs, until the age of 39 (i.e. before the 39th birthday) at the time of application).<br \/><\/p><h3>Projects: <\/h3><div class=\"rrze-elements accordion style_default\" id=\"accordion-0\">\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_0\" aria-expanded=\"false\" aria-controls=\"collapse_0\" id=\"collapse_button_0\"> P136: Deciphering the effects of tyrosine kinase inhibitor therapy on bone metabolism and longitudinal growth <\/button><\/h2>\n<div id=\"collapse_0\" class=\"accordion-body\" aria-labelledby=\"collapse_button_0\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2025 - 30. June 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Stephanie Sembill Sembill<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">As a result of non-specific inhibition, tyrosine kinase inhibitors (TKIs) also affect bone and cartilage development. Children and adolescents therefore suffer from significant growth retardation during therapy. Alternative therapy concepts are therefore urgently needed. In the proposed project, the influences of different TKIs on bone metabolism and cartilage differentiation will be investigated.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/336802815?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_1\" aria-expanded=\"false\" aria-controls=\"collapse_1\" id=\"collapse_button_1\"> P158: CSF1R-interactome analysis to identify signaling modulators in HDLS  <\/button><\/h2>\n<div id=\"collapse_1\" class=\"accordion-body\" aria-labelledby=\"collapse_button_1\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2025 - 30. June 2026<\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) is a fatal adult-onset neurological disease caused by pathological variants in CSF1R (colony-stimulating factor-1 receptor). As microglia are primarily affected in HDLS, we developed an iPSC-derived microglia model to study CSF1R function in healthy and HDLS patient lines. Using this model, we propose to investigate novel CSF1R interactions using APEX2-based proximity labeling focusing on transcriptional regulation. <\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/336798209?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_2\" aria-expanded=\"false\" aria-controls=\"collapse_2\" id=\"collapse_button_2\"> P159: Investigating the Impact of Indirect Pulp Capping on Dental Pulp Cells: An In Vitro 3D-Model Exploration <\/button><\/h2>\n<div id=\"collapse_2\" class=\"accordion-body\" aria-labelledby=\"collapse_button_2\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. June 2025 - 31. May 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Ella Ohlsson<\/span><\/p>\n<div class=\"person-card\">\n<div class=\"fau-person card-xsmall shrink-contact person-card\">\n<div class=\"card-item card-xsmall shrink-contact\" itemscope itemtype=\"http:\/\/schema.org\/Person\">\n<figure itemprop=\"image\" class=\"person-thumb\" aria-hidden=\"true\" role=\"presentation\" itemtype=\"http:\/\/schema.org\/ImageObject\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-227x300.jpg\" itemprop=\"contentUrl\" alt=\"Ella Ohlsson\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-227x300.jpg 227w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-775x1024.jpg 775w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-768x1015.jpg 768w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-1163x1536.jpg 1163w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-1550x2048.jpg 1550w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-120x160.jpg 120w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-45x60.jpg 45w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-83x110.jpg 83w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-182x240.jpg 182w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-242x320.jpg 242w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-356x470.jpg 356w, https:\/\/www.izkf.med.fau.de\/files\/2024\/10\/Ohlsson-scaled.jpg 1938w\"><meta itemprop=\"width\" content=\"227\"><meta itemprop=\"height\" content=\"300\"><\/figure>\n<h3><a href=\"https:\/\/www.izkf.med.fau.de\/person\/ella-ohlsson\/\"><span itemprop=\"name\"><span itemprop=\"honorificPrefix\">Dr.<\/span> <span class=\"fullname\"><span itemprop=\"givenName\">Ella<\/span> <span itemprop=\"familyName\">Ohlsson<\/span><\/span><\/span><\/a><\/h3>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"abstract\">Indirect capping of the dental pulp is recommended in deep cavities, but there is little clinical evidence for the success of the procedure. In an innovative simulation model of the pulp-dentin-complex, the effect of different biocompatible capping materials on human pulp cells through a dentin barrier will be tested. By analyzing cell survival, gene expression, oxidative stress and cytokine production, their bioactive effects will be compared in a way that is not possible in vivo.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/332047192?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_3\" aria-expanded=\"false\" aria-controls=\"collapse_3\" id=\"collapse_button_3\"> P160: AI-based registration for robust metabolic &amp; multi-parametric brain imaging at 7T <\/button><\/h2>\n<div id=\"collapse_3\" class=\"accordion-body\" aria-labelledby=\"collapse_button_3\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2025 - 30. June 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Angelika Mennecke<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Our overarching goal is to enable robust metabolic & multi-parametric brain MRI at 7T in a clinical context. Therefore, a fast and precise motion correction is important, which we aim to realize in this ELAN-project by a deep learning-based registration. From the specific 7T contrasts of interest such as CEST and QSM, at first a virtual reference MPRage will be synthesized, which is registered in the following. <\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/347995578?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_4\" aria-expanded=\"false\" aria-controls=\"collapse_4\" id=\"collapse_button_4\"> P162-OA: Investigating biological links between chronic stress and epigenetic dysregulation <\/button><\/h2>\n<div id=\"collapse_4\" class=\"accordion-body\" aria-labelledby=\"collapse_button_4\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2025 - 30. June 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Tomohisa Toda<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Chronic stress has long-lasting effects on the hippocampal function, but it still remains unclear how. We investigate stress-induced epigenetic changes as a biological link between chronic stress and brain dysfunction. Our preliminary data has identified lamin B1 as a target of chronic stress. Lamin B1 is an epigenetic factor that maintains heterochromatin. We will investigate how chronic stress downregulates lamin B1, and how stress-induced reduction of lamin B1 affects epigenetic regulation. <\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/335669798?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_5\" aria-expanded=\"false\" aria-controls=\"collapse_5\" id=\"collapse_button_5\"> P165-OA: Lipid nanoparticles for targeted delivery of HIV-1 antigens and genetic immunomodulators <\/button><\/h2>\n<div id=\"collapse_5\" class=\"accordion-body\" aria-labelledby=\"collapse_button_5\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2025 - 30. June 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Vladimir Temchura<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">This project aims to develop lipid nanoparticle (LNP) vaccines for targeted delivery of HIV-1 antigens and checkpoint inhibitors (CPI) mRNA. By displaying HIV-1 antigens on the LNP surface, we seek to efficiently target and activate Env-specific B cells. Concurrent delivery of CPI mRNA into the cells is anticipated to induce local checkpoint inhibitor production, modulating immune response without systemic CPI exposure.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/333617772?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_6\" aria-expanded=\"false\" aria-controls=\"collapse_6\" id=\"collapse_button_6\"> P168: Crosstalk between T cells subtypes and fibroblast subsets in skin autoimmunity <\/button><\/h2>\n<div id=\"collapse_6\" class=\"accordion-body\" aria-labelledby=\"collapse_button_6\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>21. February 2025 - 20. August 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Aleix Rius Rigau<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Skin autoimmunity consist in an aberrant immune response involving complex interactions between immune and stromal cells. Systemic sclerosis (SSc) is a skin autoimmune disorder with primary fibrotic components. Distinct fibroblasts subsets relevant in SSc have been identified, but to date is not known their spatial relationships with immune cells. Their role in SLE is also unknown. We plan to use a spatial multi-omics approach to better understand these processes.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/354169568?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_7\" aria-expanded=\"false\" aria-controls=\"collapse_7\" id=\"collapse_button_7\"> P171: Development of computational methods to identify tumor peptides for immunotherapy  <\/button><\/h2>\n<div id=\"collapse_7\" class=\"accordion-body\" aria-labelledby=\"collapse_button_7\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. June 2025 - 31. May 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Sushmita Paul<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Melanoma is a significant health issue. While checkpoint inhibitors (CPIs) have improved survival, therapy-resistant melanoma remains a challenge, approx. 40% of patients not responding to CPI treatments. Enhancing coadjuvant therapies combined with CPIs is needed. Clinical studies suggest that tumor peptide vaccines can reduce CPI resistance. This project aims to develop semi-personalized TAA-based immunotherapy using tumor sequencing, machine learning, and lab experiments to improve outcomes.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/348620224?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_8\" aria-expanded=\"false\" aria-controls=\"collapse_8\" id=\"collapse_button_8\"> P173: Lymphocyte immune assays as biomarker for kidney transplanted patients under immunosuppression in sepsis <\/button><\/h2>\n<div id=\"collapse_8\" class=\"accordion-body\" aria-labelledby=\"collapse_button_8\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>15. May 2025 - 14. May 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Johanna Kurzhagen<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Kidney transplanted patients are at a high risk for infections including sepsis. In the event of sepsis, a balance must be found between potentially life-saving immune defense and trans-plant protective immunosuppression. Fort he targeted treatment of sepsis in transplant pati-ents, we intend to identify immunological and in particular lymphocytic markers that might allow a more patientoriented, individualized therapeutic management in the future.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/350024293?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_9\" aria-expanded=\"false\" aria-controls=\"collapse_9\" id=\"collapse_button_9\"> P174: Endometrial Cancer \u0096 New molecular classification in a Real-world data Evaluation <\/button><\/h2>\n<div id=\"collapse_9\" class=\"accordion-body\" aria-labelledby=\"collapse_button_9\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. August 2025 - 31. July 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Patrik P\u00f6schke<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">The application aims to investigate endometrial cancers with regard to new molecular classifications. The ENCORE project studies real-world survival based on molecular patterns, analyzes the immune environment of tumors with concurrent p53 mutations, and correlates the eosinophil to lymphocyte ratio with patient outcome. In addition, the relevance of hormone and HER2 receptors in the individual molecular subtypes is examined.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/336803114?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_10\" aria-expanded=\"false\" aria-controls=\"collapse_10\" id=\"collapse_button_10\"> P176: Garcinol as a new therapeutic option for chondrosarcoma <\/button><\/h2>\n<div id=\"collapse_10\" class=\"accordion-body\" aria-labelledby=\"collapse_button_10\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. June 2025 - 30. November 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Sebastian St\u00e4bler<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Chondrosarcomas are malignant bone tumors, which do not respond to existing chemo- and radiotherapy. Preliminary studies could show that the the natural compound Garcinol strongly reduces proliferation and colony formation of these tumor cells. Additionally, Garcinol could re-sensitize chondrosarcoma cells to the chemotherapeutic Cisplatin. We therefore want to investigate the role of Garcinol as a new therapeutic option for chondrosarcoma.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/336803981?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_11\" aria-expanded=\"false\" aria-controls=\"collapse_11\" id=\"collapse_button_11\"> P179: Muscle tissue engineering on PCL collagen I-PANi nanofiber scaffolds in the EPI loop model <\/button><\/h2>\n<div id=\"collapse_11\" class=\"accordion-body\" aria-labelledby=\"collapse_button_11\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. August 2025 - 31. July 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Lilly Mengen<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">The aim of this project is to generate differentiated, axially vascularized and neurotized skeletal muscle tissue from ADSC and myoblasts on PCL-collagen I-(PANi)-nanofiber scaffolds. For this, seeded nanofiber scaffolds of PCL-collagen I with and without Polyanilin (4%) will be implanted in the neurotized vascular loop model of the rat for 6 weeks. Afterwards the myogenic differentiation will be analysed with the hypothesis, that the addition of PANi (4%) improves myogenic differentiation.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/354109808?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_12\" aria-expanded=\"false\" aria-controls=\"collapse_12\" id=\"collapse_button_12\"> P180: Investigation of the role of AP-1 transcription factors in melanoma dormancy in a 3D-printed model <\/button><\/h2>\n<div id=\"collapse_12\" class=\"accordion-body\" aria-labelledby=\"collapse_button_12\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>15. September 2025 - 14. September 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Sonja Schmidt<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">In this project, the role of the AP-1 transcription factors in tumor dormancy of malignant melanoma is investigated. Using our 3D biofabricated dormancy model, we could show that AP-1 factors are highly expressed in dormant melanoma cells. Additionally, preliminary data indicate an impact of AP-1 factors on the development of dormancy. To shed more light on the phenomenon of tumor dormancy, the role of AP-1 and respective signaling pathways will be analyzed in our 3D printed model system.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/353781735?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_13\" aria-expanded=\"false\" aria-controls=\"collapse_13\" id=\"collapse_button_13\"> P181: Reciprocal control of metabolism and immunomodulation in adipose tissue and liver <\/button><\/h2>\n<div id=\"collapse_13\" class=\"accordion-body\" aria-labelledby=\"collapse_button_13\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. July 2025 - 31. December 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Andreas Wild<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Obesity is marked by excessive lipid accumulation, leading to chronic inflammation in adipose tissue (AT), due to an increase in inflammatory immune cells causing insulin resistance and fat accumulation in other organs like the liver. This project focuses on the role of the immunomodulatory CD83 molecule in in lipid metabolism and obesity-related immune regulation in AT and the liver, potentially providing insights for new therapeutic strategies against obesity.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/347996163?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_14\" aria-expanded=\"false\" aria-controls=\"collapse_14\" id=\"collapse_button_14\"> P184: Establishing a Kidney Organoid Model for Complement Research in Acute Kidney Injury <\/button><\/h2>\n<div id=\"collapse_14\" class=\"accordion-body\" aria-labelledby=\"collapse_button_14\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. August 2025 - 31. July 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Eva Vonbrunn<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">The aim of this project is to establish a kidney organoid model to study complement activation in acute kidney injury. The model will first be optimized in terms of complexity and structure. Once established the kidney organoids will be used for co-culture experiments with immune cells, a hypoxia model of acute kidney injury and studies of the complement system. The development of the renal organoid model will contribute to the understanding of signalling pathways and therapeutic strategies.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/347995911?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_15\" aria-expanded=\"false\" aria-controls=\"collapse_15\" id=\"collapse_button_15\"> P185_OA: The role of Hippo pathway members YAP1\/TAZ-TEAD in muscle fibers and at the neuromuscular junction <\/button><\/h2>\n<div id=\"collapse_15\" class=\"accordion-body\" aria-labelledby=\"collapse_button_15\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. October 2025 - 31. May 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Said Hashemolhosseini<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">With this bridging grant, we are requesting support for our ongoing work on the role of the Hippo signaling pathway regulators YAP1, TAZ, TEAD1 und TEAD4 in skeletal muscle, especially in early myogenesis, skeletal muscle development and in adult skeletal muscle fibers. The results of this work will help us to revise and submit our DFG proposal and manuscript (for Nucleic Acids Research) and to continue funding the PhD theses involved.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/354109506?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_16\" aria-expanded=\"false\" aria-controls=\"collapse_16\" id=\"collapse_button_16\"> P190: Investigation of EVs\u0092 protective role in developing intestine of zebrafish larvae <\/button><\/h2>\n<div id=\"collapse_16\" class=\"accordion-body\" aria-labelledby=\"collapse_button_16\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. December 2025 - 30. November 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Linda-Marie Mulzer<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Extracellular vesicles (EVs) are membrane-bound nanoparticles essential for cell communication and organogenesis. We hypothesize that human breast milk-derived EVs (HBM-EVs) enhance intestinal maturation and regeneration. This study investigates HBM-EV protection in DSS-induced intestinal injury in zebrafish larvae, analyzing cell-morphology, inflammation, and tissue repair (Phalloidin, cleaved Caspase-3, TNF-?, Wnt5a), comparing EVs from three lactation stages.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/353782249?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_17\" aria-expanded=\"false\" aria-controls=\"collapse_17\" id=\"collapse_button_17\"> P177: Generation of Synthetic Contrast-Enhanced Breast-MR Images From Native Sequences Using Deep Learning <\/button><\/h2>\n<div id=\"collapse_17\" class=\"accordion-body\" aria-labelledby=\"collapse_button_17\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. November 2025 - 30. October 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Lorenz Kapsner<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">The application of Latent Diffusion Models (LDMs) in the context of breast MRI is being investigated, aiming to generate synthetic contrast-enhanced (CE) subtraction sequences of the breast by using native MRI sequences as input for the conditioning process. The resulting images will be evaluated regarding their suitability for diagnostic  purposes. The results will help to better understand the potential and limits of LDMs in the context of generating synthetical CE breast MRI.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/358877650?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_18\" aria-expanded=\"false\" aria-controls=\"collapse_18\" id=\"collapse_button_18\"> P178: Integrative analysis of single-cell RNA-seq data to unravel CAF subtypes in PDAC mouse models <\/button><\/h2>\n<div id=\"collapse_18\" class=\"accordion-body\" aria-labelledby=\"collapse_button_18\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. February 2026 - 31. January 2027<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Renato Liguori<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">This project aims to develop a robust reference framework for CAF subtypes analysis by integrating scRNA-seq datasets from PDAC mouse models. By identifying consistent gene signatures, we will provide a foundation for studying CAF heterogeneity and their function in PDAC. The resulting dataset will enhance reproducibility in preclinical research and facilitate future studies of CAF dynamics in diverse tumor contexts.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/353784181?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_19\" aria-expanded=\"false\" aria-controls=\"collapse_19\" id=\"collapse_button_19\"> P189: Generation of recombinant vaccine candidates against BoDV-1 <\/button><\/h2>\n<div id=\"collapse_19\" class=\"accordion-body\" aria-labelledby=\"collapse_button_19\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2026 - 31. December 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Dominik Damm<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Borna Disease Virus 1 (BoDV-1) causes fatal encephalitis in humans. This project aims to generate recombinant variants of the glycoprotein G via structure-guided vaccine design. The G variants will be conjugated to the surface of liposomes that incorporate biomolecular adjuvants to boost immunogenicity. Optionally, we aim to mimic a live-attenuated vaccine by additional encapsulation of viral structural proteins. The BoDV-1 liposomes would be used in future studies with antibody-humanized mice.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/355529390?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_20\" aria-expanded=\"false\" aria-controls=\"collapse_20\" id=\"collapse_button_20\"> P186: PAINMAP-IBD: Skin Sensory Testing to Assess Visceral Nerve Dysfunction in IBD-related Abdominal Pain <\/button><\/h2>\n<div id=\"collapse_20\" class=\"accordion-body\" aria-labelledby=\"collapse_button_20\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2026 - 31. December 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Miriam D\u00fcll<\/span><\/p>\n<div class=\"person-card\">\n<div class=\"fau-person card-xsmall shrink-contact person-card\">\n<div class=\"card-item card-xsmall shrink-contact\" itemscope itemtype=\"http:\/\/schema.org\/Person\">\n<figure itemprop=\"image\" class=\"person-thumb\" aria-hidden=\"true\" role=\"presentation\" itemtype=\"http:\/\/schema.org\/ImageObject\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-250x300.jpg\" itemprop=\"contentUrl\" alt=\"Miriam D\u00fcll\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-250x300.jpg 250w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-853x1024.jpg 853w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-768x922.jpg 768w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-1279x1536.jpg 1279w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-50x60.jpg 50w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-92x110.jpg 92w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-200x240.jpg 200w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-267x320.jpg 267w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell-391x470.jpg 391w, https:\/\/www.izkf.med.fau.de\/files\/2022\/12\/duell.jpg 1635w\"><meta itemprop=\"width\" content=\"250\"><meta itemprop=\"height\" content=\"300\"><\/figure>\n<h3><a href=\"https:\/\/www.izkf.med.fau.de\/person\/miriam-duell\/\"><span itemprop=\"name\"><span itemprop=\"honorificPrefix\">Dr.<\/span> <span class=\"fullname\"><span itemprop=\"givenName\">Margareta Miriam<\/span> <span itemprop=\"familyName\">D\u00fcll<\/span><\/span><\/span><\/a><\/h3>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"abstract\">PAINMAP-IBD explores whether cutaneous sensory afferents can serve as a surrogate marker of visceral nerve dysfunction in IBD-associated abdominal pain. Using abdominal quantitative sensory testing (QST) and C-fiber-selective stimulation, the project characterizes sensory phenotypes and peripheral neurofunction. Findings will be correlated with clinical activity, biomarkers, and treatment response across defined patient cohorts.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/353832433?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_21\" aria-expanded=\"false\" aria-controls=\"collapse_21\" id=\"collapse_button_21\"> P188_OA: Allospecific Responses of Marginal Zone B Cells in Kidney Transplantation <\/button><\/h2>\n<div id=\"collapse_21\" class=\"accordion-body\" aria-labelledby=\"collapse_button_21\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. March 2026 - 28. February 2027<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Louisa Steines<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Rejection is a major cause of allograft failure. The role of marginal zone B cells in kidney transplantation is unkown. In this project, we will investigate the donor-specific responses of marginal zone B cells using a rat kidney transplantat model. Specifically, we will determine the capacity of marginal zone B cells to produce anti-donor antibodies, to secrete inflammatory or regulatory cytokines and the sensitivity towards anti-BAFF antibody treatment in a kidney transplant model.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/358877948?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_22\" aria-expanded=\"false\" aria-controls=\"collapse_22\" id=\"collapse_button_22\"> P195: On the role and consequence of LINE-1 retroelements in extracellular vesicles <\/button><\/h2>\n<div id=\"collapse_22\" class=\"accordion-body\" aria-labelledby=\"collapse_button_22\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2026 - 31. December 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Thomas Gramberg<\/span><\/p>\n<div class=\"person-card\">\n<div class=\"fau-person card-xsmall shrink-contact person-card\">\n<div class=\"card-item card-xsmall shrink-contact\" itemscope itemtype=\"http:\/\/schema.org\/Person\">\n<figure itemprop=\"image\" class=\"person-thumb\" aria-hidden=\"true\" role=\"presentation\" itemtype=\"http:\/\/schema.org\/ImageObject\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-250x300.jpg\" itemprop=\"contentUrl\" alt=\"Prof. Dr. Thomas Gramberg\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-250x300.jpg 250w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-853x1024.jpg 853w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-768x922.jpg 768w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-1280x1536.jpg 1280w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-50x60.jpg 50w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-92x110.jpg 92w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-200x240.jpg 200w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-267x320.jpg 267w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg-392x470.jpg 392w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/gramberg.jpg 1649w\"><meta itemprop=\"width\" content=\"250\"><meta itemprop=\"height\" content=\"300\"><\/figure>\n<h3><a href=\"https:\/\/www.izkf.med.fau.de\/person\/prof-dr-thomas-gramberg\/\"><span itemprop=\"name\"><span itemprop=\"honorificPrefix\">Prof. Dr.<\/span> <span class=\"fullname\"><span itemprop=\"givenName\">Thomas<\/span> <span itemprop=\"familyName\">Gramberg<\/span><\/span><\/span><\/a><\/h3>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"abstract\">LINE-1 retroelements (L1) are upregulated in many autoimmune diseases, including  SLE. Although L1 replicates intracellularly, we found L1 RNA packaged in extracellular vesicles (EV) in sera from SLE patients. Since L1 nucleic acids can trigger inflammatory pathways, we hypothesize that L1-EVs impact pathogenesis and could be used as novel biomarker in patients. Also, we ask whether L1 can be mobilized via EVs, challenging the dogma of L1s as intracellular pathogen.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/360898472?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion-group\">\n<h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\"  href=\"#collapse_23\" aria-expanded=\"false\" aria-controls=\"collapse_23\" id=\"collapse_button_23\"> P183: Molecular characterisation of the remission mediated by CAR T cells in Systemic Lupus Erythematosus <\/button><\/h2>\n<div id=\"collapse_23\" class=\"accordion-body\" aria-labelledby=\"collapse_button_23\">\n<div class=\"accordion-inner clearfix\"><strong>Term: <\/strong>1. January 2026 - 31. December 2026<br \/><strong>Project leader: <\/strong><span class=\"author\" itemprop=\"author\">Panagiotis Garantziotis<\/span><\/p>\n<div class=\"person-card\"><\/div>\n<\/p>\n<p class=\"abstract\">Despite progress in understanding SLE, remission is rare. A \"treat-to-target\" approach aims to minimize disease activity, reducing organ damage and flares. B-cell immunity transcriptional signature correlates with treatment response, with effective therapy requiring its reversal. CAR T cells show promise for sustained, drug-free remission. Here, we will delineate transcriptional fingerprints of treatment response and resistance to uncover molecular drivers of effective therapy and remission.<\/p>\n<p>&#8594; <a href=\"https:\/\/cris.fau.de\/projects\/361203381?lang=en_GB\">More information<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1355,"featured_media":1920,"parent":6971,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"page-templates\/page-subnav.php","meta":{"_rrze_cache":"enabled","_access_permission":"","_rrze_multilang_single_locale":"en_GB","_rrze_multilang_single_source":"https:\/\/www.izkf.med.fau.de\/?page_id=1793","footnotes":""},"page_category":[],"page_tag":[],"workflow_usergroup":[],"class_list":["post-7008","page","type-page","status-publish","has-post-thumbnail","hentry","en-GB"],"_links":{"self":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/7008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/users\/1355"}],"replies":[{"embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/comments?post=7008"}],"version-history":[{"count":6,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/7008\/revisions"}],"predecessor-version":[{"id":109357,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/7008\/revisions\/109357"}],"up":[{"embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/6971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/media\/1920"}],"wp:attachment":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/media?parent=7008"}],"wp:term":[{"taxonomy":"page_category","embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/page_category?post=7008"},{"taxonomy":"page_tag","embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/page_tag?post=7008"},{"taxonomy":"workflow_usergroup","embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/workflow_usergroup?post=7008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}